Sino Biopharmaceutical (HK:1177) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sino Biopharmaceutical has received approval to market its KRAS G12C inhibitor, Garsorasib, in China for advanced non-small cell lung cancer, offering a promising new treatment option for patients with limited choices. The drug demonstrated strong efficacy in clinical trials, showing significant improvement in survival rates compared to other options. This approval positions Garsorasib as a key player in precision-targeted cancer therapies, with potential for expansion to other indications.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.